NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The later patents of Tjoa have nothing to do with the issue.

The patent listed as grounds for the rejection (in the one case barcode posted) was 9102917. This is a continuation of the core "DC maturation" patent of NWBO. "Tjoa" is used by the examiner to name it as they always use the inventor, but NWBO is the assignee.

So the problem is not somebody else having a patent, it is that NWBO's later patent applications are obvious based on earlier patents.

In this particular case the earlier patent is a continuation of 8,389,278 which dates back to Feb 2003. And thus, as Barcode says, is running out of time.

It is unclear if the '278 patent is the tech -L uses, or is only for Direct. NWBO has never been clear on this (understandably). If it is used in -L, then they could get an extension until early 2028 if they get approval prior to Feb 2023.

If the '278 patent is not being used in -L, then the entire patent portfolio is virtually worthless w/o getting any existing applications approved. And that is why NWBO is pressing them.